Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Cell therapy developer for cancer and autoimmune diseases, using FasTCAR and TruUCAR platforms.
Gracell Biotechnologies, based in Shanghai, China, develops innovative cell therapies for cancer and autoimmune diseases, leveraging its proprietary FasTCAR and TruUCAR platforms. The clinical-stage biopharmaceutical company focuses on creating autologous and allogeneic CAR-T product candidates designed to overcome challenges such as lengthy manufacturing and limited efficacy in solid tumors. Gracell has secured significant capital, including a $150 million private placement in August 2023 led by Vivo Capital, and an $85 million Series B round in February 2019. Other notable investors in the company include OrbiMed, RA Capital Management, and Temasek. The company's pipeline aims to address unmet medical needs in both hematological malignancies and autoimmune conditions. Gracell Biotechnologies was founded in May 2017 by Dr. William Wei Cao and his co-founding team.
Gracell Biotechnologies has raised $185.0M across 2 funding rounds.
Gracell Biotechnologies has raised $185.0M in total across 2 funding rounds.
Gracell Biotechnologies has raised $185.0M in total across 2 funding rounds.
Gracell Biotechnologies's investors include Morningside Ventures, OrbiMed, Wellington Management, King Star Med, Lilly Asia Ventures, Temasek Holdings, Vivo Capital, Temasek, Chengdu Miaoji, King Star Capital, Kington Capital.
Gracell Biotechnologies has raised $185.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 29, 2020 | $100M Series C | Morningside Ventures, OrbiMed, Wellington Management | King Star MED, Lilly Asia Ventures, Temasek Holdings, Vivo Capital | Announced |
| Feb 25, 2019 | $85M Series B | Temasek | Chengdu Miaoji, King Star Capital, Kington Capital, Lilly Asia Ventures | Announced |